Enterprise Value
-15.26M
Cash
38.8M
Avg Qtr Burn
-17.69M
Short % of Float
9.03%
Insider Ownership
1.10%
Institutional Own.
64.93%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
FLT201 Details Genetic disorder | Phase 1/2 Data readout | |
FLT180a (AAVS3 capsid) Details Hemophilia | Failed Discontinued | |
FLT190 Details Genetic disorder, Fabry disease | Failed Discontinued |